Department of Cardiovascular Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong 510180, China.
Department of Cardiology, The PLA 74th Group Army Hospital, China.
Dis Markers. 2022 Jun 28;2022:2751750. doi: 10.1155/2022/2751750. eCollection 2022.
Acute ST-segment elevation myocardial infarction (STEMI) is a serious multiple acute cardiovascular disease. This study investigated the effect of statins on the efficacy and prognosis of STEMI patients after emergency PCI.
From October 2019 to January 2021, 98 patients with STEMI in our hospital were selected and divided into study group and control group. The study group took atorvastatin 40 mg 2 hours before surgery, 40 mg/day after surgery, and 20 mg/day 1 week later. The control group received 20 mg of atorvastatin every night after admission. The cardiac output, left ventricular ejection fraction, blood flow classification, vagus nerve function, heart rate deceleration force and chemoreflex sensitivity were compared between the two groups, and recorded the incidence of adverse reactions before and after treatment and 3 months after treatment. The number of major adverse cardiac events (MACEs) was also recorded.
Before treatment, there were no differences in CO, CI, and LVEF between the study and control groups. After treatment, CO, CI, and LVEF in the study group were significantly higher than those in the control group. Before treatment, there was no significant difference in TIMI blood flow classification among the groups, and after treatment, the study group was better than the control group. DC and ChRS were significantly higher in the study group than in the control group. There was no difference in the incidence of adverse reactions between the study group and the control group. However, the incidence of MACE in the study group was lower than that in the control group.
Enhanced-dose atorvastatin for STEMI patients improved PCI treatment effect, cardiac function, and vagus nerve function and reduced the incidence of adverse cardiac events. Thus, statins are safe and worth considering.
急性 ST 段抬高型心肌梗死（STEMI）是一种严重的多发性急性心血管疾病。本研究探讨了他汀类药物对急诊 PCI 后 STEMI 患者疗效和预后的影响。
选取我院 2019 年 10 月至 2021 年 1 月期间收治的 98 例 STEMI 患者，分为研究组和对照组。研究组术前 2 小时给予阿托伐他汀 40mg，术后每日 40mg，1 周后每日 20mg；对照组入院后每晚给予 20mg 阿托伐他汀。比较两组心输出量、左心室射血分数、血流分级、迷走神经功能、心率减速力和化学反射敏感性，记录治疗前后及治疗后 3 个月不良反应的发生率，记录主要不良心脏事件（MACE）的发生情况。
治疗前，两组 CO、CI 和 LVEF 比较，差异无统计学意义。治疗后，研究组 CO、CI 和 LVEF 明显高于对照组。治疗前，两组 TIMI 血流分级无显著差异，治疗后研究组优于对照组。研究组 DC 和 ChRS 明显高于对照组。研究组不良反应发生率与对照组比较差异无统计学意义。然而，研究组 MACE 的发生率低于对照组。
对于 STEMI 患者，强化剂量阿托伐他汀可改善 PCI 治疗效果、心功能和迷走神经功能，降低不良心脏事件的发生率。因此，他汀类药物是安全的，值得考虑。
